Idaho

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. Because Idaho allows asynchronous-first care under the Idaho Virtual Care Access Act, an Idaho-licensed clinician can review your intake by secure message and prescribe without a scheduled video visit, unless your history calls for one. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Idaho address in 2–3 business days.

The process is the same as for semaglutide — complete Pallas's online intake, and an Idaho-licensed clinician reviews it asynchronously under the Idaho Virtual Care Access Act, without a required video visit. If appropriate, your clinician can prescribe either compounded tirzepatide, prepared per-patient by a US-licensed §503A pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is legal and available to eligible Idaho residents through licensed telehealth. It is prepared per-patient by US state-licensed 503A and 503B compounding pharmacies under FDCA §503A, and an Idaho-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas works only with US state-licensed compounding pharmacies and serves Idaho with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes. Idaho recognizes full-practice authority for nurse practitioners — under Idaho Code §54-1402, NPs licensed by the Idaho Board of Nursing can prescribe semaglutide and tirzepatide independently, without a collaborative agreement or physician supervision. Every Pallas clinician who treats Idaho patients holds an active Idaho license appropriate to their role.

Several licensed telehealth platforms serve Idaho residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in Idaho, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Idaho residents and is LegitScript Healthcare Merchant Certified.

No — Idaho allows asynchronous-first care under the Idaho Virtual Care Access Act. A licensed Idaho provider can review your intake by secure message and prescribe semaglutide without a scheduled video visit, as long as the standard of care is met. Your provider may request a video visit or additional information only if your history calls for it.

Most Idaho patients complete online intake in about five minutes, and an Idaho-licensed clinician typically reviews it within 1–2 business days, since Idaho allows asynchronous-first care under the Idaho Virtual Care Access Act with no mandatory video visit. If semaglutide is clinically appropriate, your prescription goes to a US-licensed pharmacy, which ships to any Idaho address in 2–3 business days after filling. An incomplete intake, a missing ID or photo, or a clinician requesting a follow-up video visit can add time — there is no guaranteed timeline, since review depends on your individual history.

Yes — telehealth access through Pallas is the same across Idaho, whether you're in Boise, Meridian, Nampa, Idaho Falls, or Coeur d'Alene in the Panhandle. An Idaho-licensed clinician reviews every intake the same way regardless of ZIP code, and licensed partner pharmacies ship both compounded medications and FDA-approved brands like Zepbound^® to any Idaho address, including rural counties in the Magic Valley and eastern Idaho. Distance from a major metro does not change your eligibility or your care.

Several telehealth providers prescribe tirzepatide to Idaho residents. Before choosing one, verify that its clinicians hold an active Idaho medical license, that it works with US-licensed §503A compounding pharmacies (or offers FDA-approved Zepbound^®/Mounjaro^® as the brand-name option), and that it carries LegitScript Healthcare Merchant Certification — checkable in LegitScript's public database. Pallas serves Idaho residents and is LegitScript Healthcare Merchant Certified.

Most Idaho patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Boise, Meridian, Nampa, and Idaho Falls typically ship fastest; rural and mountain ZIP codes may take an extra day.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Idaho address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Boise, Idaho Falls, or a rural Idaho ZIP code. Idaho Medicaid covers GLP-1s for type 2 diabetes with prior authorization, but coverage for weight-management indications is limited and compounded GLP-1s are not covered — either way, Medicaid rules do not apply to Pallas's cash-pay prescriptions.

In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Eligibility is always decided by an Idaho-licensed clinician after reviewing your full intake, never by an automated quiz — your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Idaho-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Idaho-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Idaho State Board of Medicine reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Idaho address, usually within 2–3 business days.

Yes — your plan renews on a regular cadence so your medication arrives before you run out. Your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects along the way. You can message your care team from the Pallas app or your patient portal, and change your plan or cancel anytime from the portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 first month, then $597 every 12 weeks ($199/mo average), charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Idaho address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $897 every 12 weeks ($299/mo average), charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Idaho address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Idaho patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Idaho during intake.

Coverage of GLP-1 medications for weight loss through Medicaid is limited. Idaho Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited, and compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid coverage does not apply to our prescriptions. Pallas is a cash-pay telehealth service — we do not bill Medicaid or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in Idaho, and neither requires insurance. One: stay on FDA-approved Wegovy^® or Zepbound^® at flat cash-pay pricing from $1069/mo. Two: if a clinician licensed in Idaho determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $597 every 12 weeks ($199/mo average), charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $897 every 12 weeks ($299/mo average), charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Idaho weighs your history, goals, and budget to recommend a starting point.